Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | PKM | P14618 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | EBP | Q15125 | 1/20 | 0.57 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9535608 | 0.95 | LMNA (0.60) | ALDH1A1PKMPOLBHTTKDM4E | |
| SCHEMBL3235046 | 0.90 | PKM (0.57) | ALDH1A1PKMPOLBHTTKDM4E | |
| SCHEMBL4516709 | 0.90 | PKM (0.57) | ALDH1A1PKMPOLBHTTKDM4E | |
| SCHEMBL3235054 | 0.90 | PKM (0.57) | ALDH1A1PKMPOLBHTTKDM4E | |
| SCHEMBL10360133 | 0.90 | HSD11B1 (0.67) | ALDH1A1PKMPOLBHTTKDM4E | |
| SCHEMBL28882522 | 0.84 | ALDH1A1 (0.66) | ALDH1A1PKMPOLBHTTKDM4E | |
| SCHEMBL12793343 | 0.84 | USP2 (0.71) | ALDH1A1POLBHTTKDM4EHSD11B1 | |
| SCHEMBL266466 | 0.84 | MEN1 (0.77) | ALDH1A1PKMPOLBHTTKDM4E | |
| SCHEMBL2474562 | 0.83 | ALDH1A1 (0.62) | ALDH1A1PKMPOLBHTTKDM4E | |
| SCHEMBL565301 | 0.83 | PKM (0.88) | ALDH1A1PKMPOLBHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4413012-A1 | PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE | Studiengesellschaft Kohle gGmbH (DE) | 2024-08-14 | — | — | EP | disclosed |
| CN-117164505-A | Method for synthesizing organic sulfate by dialkyl sulfate or pyrosulfate | 湖南大学 | 2023-12-05 | — | — | CN | disclosed |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | GONGWIN BIOPHARM CO., LTD (TW) | 2023-10-12 | — | — | US | disclosed |
| US-11752118-B2 | Method for treating melanoma | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | GONGWIN BIOPHARM CO., LTD (TW) | 2023-09-12 | — | — | US | disclosed |
| WO-2023110394-A1 | PROCESS FOR C-H INSERTION BY GEM-HYDROGENATION OF AN INTERNAL ALKYNE | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| US-20220168248-A1 | METHOD FOR TREATING MELANOMA | GONGWIN BIOPHARM CO., LTD (TW) | 2022-06-02 | — | — | US | disclosed |
| US-20200338028-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR MODULATING LIPID RAFT | GONGWIN BIOPHARM CO., LTD. (TW) | 2020-10-29 | — | — | US | disclosed |
| US-10548862-B2 | Topical formulation and method for preventing or treating acne | Wu, Lester J. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190321313-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER | Gongwin Biopharm Holdings Co., Ltd. | 2019-10-24 | — | — | US | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006008260-A1 | DIMERIC PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-26 | — | — | WO | disclosed |
| EP-0151826-B1 | 4-[(Bicyclic heterocyclyl)-methyl and -hetero]-piperidines | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-03-31 | — | — | EP | disclosed |
| US-5070087-A | Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1991-12-03 | — | — | US | disclosed |
| US-4950674-A | Arylalkylheterocyclic amines,N-substituted by aryloxyalkyl group in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1990-08-21 | — | — | US | disclosed |
| US-4839374-A | TREATING ALLERGIES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1989-06-13 | — | — | US | disclosed |
| US-4810713-A | Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl groups used in a method for allergy treatment | A. H. ROBINS COMPANY, INCORPORATED (US) | 1989-03-07 | — | — | US | disclosed |
| US-4695575-A | ANTIHISTAMINES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1987-09-22 | — | — | US | disclosed |
| EP-0235463-A2 | N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1987-09-09 | — | — | EP | disclosed |
| EP-0151826-A1 | 4-[(Bicyclic heterocyclyl)-methyl and -hetero]-piperidines | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321313-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER | ARSA, ABCB1, ABCG2 | ALDH1A1 689/4885PKM 1749/4885POLB 1930/4885 |
| US-10548862-B2 | Topical formulation and method for preventing or treating acne | CUTA, STS, ALAD | ALDH1A1 669/4885PKM 2529/4885POLB 2365/4885 |
| US-11752160-B2 | Method for reducing fat by administering benzenesulfonamide compositions | LIPE, FABP4, LIPA | ALDH1A1 728/4885PKM 521/4885POLB 1703/4885 |
| US-20220168248-A1 | METHOD FOR TREATING MELANOMA | TYR, MITF, BRAF | ALDH1A1 528/4885PKM 1050/4885POLB 1410/4885 |
| US-20230321016-A1 | COMBINATION THERAPY FOR TREATING CANCER | TP53, MCL1, TOP2B | ALDH1A1 381/4885PKM 2022/4885POLB 907/4885 |
| US-11752118-B2 | Method for treating melanoma | TYR, MITF, BRAF | ALDH1A1 528/4885PKM 1050/4885POLB 1410/4885 |
| US-20200338028-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR MODULATING LIPID RAFT | ABCB4, SPTSSB, SMPD2 | ALDH1A1 1604/4885PKM 2929/4885POLB 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.